Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents.

Epidemiological data clearly indicate a link between hepatitis C virus (HCV) and altered glucose homeostasis. To evaluate the response of treatment with direct antiviral agents (DAAs) on metabolic variables of patients with hepatitis C. Observational, cross-sectional study in a sample of patients with hepatitis C starting therapy with DAAs followed on the hepatology division of Federal University of Rio de Janeiro State. Data were collected in two stages: before the start of therapy and between 12 and 52 weeks after obtaining the sustained virological response. In the baseline assessment of the 97 patients selected, 19.3% were obese, 38.6% were overweight, 50% were hypertensive, 43.8% were pre-diabetic, 12.5% were diabetic, 31.2% were dyslipidemic, and 21.8% had metabolic syndrome. There was an increase in total cholesterol and LDL levels ( < 0.001), and a non-significant reduction in blood glucose, glycated hemoglobin, insulin, and HOMA-IR levels after treatment. In the post-treatment, there was a reduction in fibrosis ( = 0.016), with a reduction in the levels of GGT, AST, and ALT (all with < 0.001), as well as in the FIB4 and APRI scores (both with < 0.001) and in the degree of fibrosis evaluated by elastography represented in kPa ( = 0.006). The blood glucose level was higher in patients with steatosis ( = 0.039) after treatment. There was a positive pre-treatment correlation between the degree of fibrosis (kPa) and FIB4 ( = 0.319, = 0.004), APRI ( = 0.287, = 0.010), and the NAFLD score ( = 0.275, = 0.016). Patients with hepatitis C had a high prevalence of metabolic disturbance in the pre-treatment phase, but the therapy did not show beneficial effects, especially on glucose metabolism.